Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study.
Orthocell completes all nerve repair surgeries in Remplir US market authorisation study
March 25, 2024 Australian Biotech
Latest Video
New Stories
-
'Patient-centric partnerships will unlock brighter and more equitable outcomes for all'
October 21, 2025 - - Latest News -
Vaccine confidence slips as Australians grow more concerned about access to healthcare
October 20, 2025 - - Latest News -
NZ's Pharmac proposes new rules to manage 'Options for Investment' list - make it shorter
October 20, 2025 - - Latest News -
Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies
October 20, 2025 - - Australian Biotech -
Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum
October 20, 2025 - - Australian Biotech -
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 - - Australian Biotech -
Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion
October 20, 2025 - - Latest News